throbber
Petitioner Amerigen Pharmaceuticals Ltd.
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1013 - Page 1
`
`

`
`Petitioner Amerigen Pharmaceuticals Ltd.
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1013 - Page 2
`
`

`
`Petitioner Amerigen Pharmaceuticals Ltd.
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1013 - Page 3
`
`

`
`Petitioner Amerigen Pharmaceuticals Ltd.
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1013 - Page 4
`
`

`
`
`
`component. that will pharmacologically antagonize an
`unfavorable property or properties exhibited by the basic
`agent. Salts of N -cyclohexylsulfamic acid are an example
`of the practical application of this approach. N-Cyclo-
`hexylsulfamic acid salts, better known as cyclamates, have
`a characteristic sweet, pleasing taste. Although presently
`under investigation by the FDA for potentially carcino-
`genic properties, salts incorporating this compound can
`render unpleasant or bitter—tasting drugs acceptable. For
`example.
`the cyclamates of dextromethorphan and
`chlorpheniramine exhibit. gfeatly improved bitterness
`thresholds compared to corrunonly occurring salts (31).
`Furthermore, their stability in aqueous solution was de-
`scribed as good when maintained at a pH not greater than
`4.
`
`N-Cyclohexylsulfarnic acid salts of thiamine hydro-
`chloride and lincomycin also have been synthesized. Thi-
`amine N -cyclohexylsulfamate hydrochloride was reported
`to have a more pleasant taste than other thiamine salts
`while having an equal or greater stability (32). Lincomycin
`cyclamate, shown t.o possess an enhanced thermal stability
`over its hydrochloride, was prepared {B3} to test the hy-
`pothesis that reduced lincomycin absorption in the pres-
`ence of small quantities ofcyclamates was due to a simple
`metathetic reaction. However, this assumption was found
`not to be true. An extensive study of the preparation and
`characterization of cyclamic acid salts of several widely
`used classes ofdrugs including antihistamines. antibiotics.
`antitussives, rnyospasinolytics, and local anesthetics was
`reported (34, 135}.
`Various salts of penicillin and basic amine compounds
`have been formulated in an effort to produce a long-acting,
`nonallergenic Form of penicillin. Since antihistamines
`appear to mitigate the syniptomatology of penicillin re-
`acl.ions in some patients, coadministration of the two has
`been advocated. The preparation of the henzhydralamine
`salt of penicillin was an attempt. to produce a repository
`form of penicillin with antiallergic properties (36). Blood
`levels achieved with this salt were comparable to those of
`penicillin G potassium; however, it.s antiallergic properties
`were not evaluated- In fact, the investigators noted that
`antihistamines can actually cause sensitization at times
`and stated that. “despite their occasionally l'avorable in-
`fluence on the svmptorns of penicillin sensitivity, they
`contribute directly to the potential of drug sensitivity when
`co-administered with penicillin."
`Silver salts of sulfanilarnide, penicillin, and other anti-
`biotics have been prepared and represent cases where the
`species {ions} are complementary. When aqueous solutions
`of the salts were applied topically to burned tissue, they
`yielded the combined benefits of the oligodynarnic action
`of silver and the advantages of the. antibacterial agents
`(37).
`
`The use of 8-substituted xanthines, particularly the
`8-substituted theophyllines. as salt—forming agents was
`lirst reported in the preparation ofa series ofantihislamine
`salts (38-41). Synthesis of these xanthine salts was an at-
`tempt. to find a drug to counteract the drowsiness caused
`by the antihistamines with the stimulant properties of the
`xanthines. When an electroncgative group is introduced
`into the xanthine molecule at the 8-position, the elec-
`tron—drawing capacity of the substituent results in the
`creation of an acidic hydrogen at position 7. Thus. these
`
`-I
`
`/I Jon-rriol of .{'I.lI[I.l'l'Ti('l,(,'L-'Hl‘!IL'«'I.f .5(‘lii?n.L'r'.s
`
`moderately strong acidic compounds can undergo salt
`formation with various organic bases.
`The 8—l1alotheophyllines were the first group of san-
`thines studied as potential salt-forming agents. Since the
`report on the preparation of the 8-chlorotheophylline salt
`of diphenhydramine (42), synthesis of the 8-ha_lotheo-
`phyllinates of a number of organic bases has been at-
`tempted. The 8-chlorotheophylline salts of quinine,
`ephedrine, and strychnine were prepared and character-
`ized (43). These salts were less water soluble than the
`corresponding free alkaloidal bases. In a similar report, the
`8-chlorotheophyllinates of
`three synthetic narcotics.
`meperidlne, levorphanol, and metopon, were prepared
`(44).
`
`Pharmacological and clinical studies involving the 8-
`hromotheophylline pyrilamine salt revealed the unusual
`diuretic properties associated with the S8-halotheophylline
`portion of the compound (45, 46}. This finding initiated
`an investigation into the preparation of a soluble 8-bro
`motheophylline salt of high diuretic activity. With readily
`available amines, over 30 salts were synthesized and
`screened for diuretic activity (47). When tested against
`theophylline salts of the same amines, the 8-bromotheo
`phyllinates showed greater activity in every case.
`With the successful formation of 8-halotheophyllinates
`of organic bases, Morozowich and Hope (48) proposed that,
`if the halogen moiety was replaced with a more electro-
`negative substituent such as a nitro group, a more acidic
`compound would be formed. Presumably, more stable salts
`would result and precipitation of the free xanthine deriv-
`ative in the stomach would be less likely to occur. On this
`premise, they successfully prepared pharmacologically
`effective 8-nitrotheophyllinates of several pharmaceuti-
`cally useful bases.
`Duesel et al. (19), in their study of choline theophylli-
`nate, prepared the 8-chloro-. 8—bromo-, and 8-nitrotheo
`phylline salts of choline. Oral toxicity studies in mice
`showed that the LD.-an of the 8-nitrotheophyllinate was
`much greater than that of either 8-halul.heoph_vlline. In
`fact, it remained nonlethal at doses as high as 5 g.
`Polygalacturonic acid, a derivative of pectin, has been
`used to prepare quinidine salts exhibiting reduced toxicity
`[49, 50). The compound possesses special dernulcent
`properties and inhibits mucosal irritation. The rationale
`for use of this agent is to reduce the ionic shock to the GI
`mucosa resulting from the flood of irritating ions liberated
`by rapid dissociation of the conventional inorganic quin-
`idine salts. Studies have shown that it is four times less
`toxic orally than the sulfate. This difference was attributed
`to the slower release of quinidine from the pol_vgalactu-
`ronate.
`
`Other compounds reported to be potentially useful as
`pharmaceutical salt forms are listed in Table III.
`
`PHYSICOCHEMICAL STUDIES
`
`Biological activity of a drug molecule is influenced by
`two factors: its chemical structure and effect at a specific:
`site and its ability to reach—and then he removed from—
`the site ofaction. Thus, a knowledge ofthe physicochem
`lcal properties ot' a compound that influence its absorption.
`distribution, metabolism, and excretion is essential for a
`complete understanding of the onset and duration of ac-
`
`Table H‘l—
`
`Hal I
`
`Acel.vlan:inot
`N-Acelyl-I.-a
`N -A ct-lylcvsl
`Arlatnanloic 2
`l"\rlipi1:3Cl[l
`N .-’\ll«i_vlsuil‘aI
`
`Anlhrncguinoi
`firrnlnogalarlas
`:‘\rginine
`
`Aspartale
`Bolaine
`Hisiil-carhm<_\
`['.arnitine
`-1-C‘.hluro—m—II
`l'}ei.-anoate
`[Jiacclyl sulfa
`[lilaenz_vIet.hy|
`Tlielhvloinine
`l"liguaiac_v| ph
`llioctyl sull'n.r-'.
`Pmb: mic {pan
`
`l“-'l‘l.l[?l.ll5t'- l.£i-G‘
`
`Gin:-.1 use l-pllu
`l'i-pho:-.ph_ori
`1.-tilulamine
`H_vdrr:_\;ynnph
`3—l-1-lrnidagmlg
`lsrnialllalirnlaln
`Lau ryl su ll'aI.e
`Lys: ne
`Mel l1.'!I'|l:Rtlll-L].
`N- Met liylgluc
`
`N -iVlet.hy|pipe
`l\1lnrphollne
`3-N.’-]}}l‘l1.llF1l(~‘.rlI
`fl:-I ant u1l.{-‘
`Pr: uhe ne:.-iii
`'l‘a1111lc:Jt-id
`Theobromine.
`H,-l.5-"l'rimt‘lh(
`
`’l'romel haminr
`
`tion, the rel
`ministratior
`in a reviei
`“different se
`logically; the
`properties."
`panded upoi
`nature of th
`salts of the s
`ciahly. their
`The salt fr
`
`cocheinical [
`dissolution r
`These propc
`rnulation ch
`pharrnaceutl
`extensive pr.
`properties of
`suitable forn:
`
`concerning s
`tion studiesi
`salt form on
`under invest
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1013 - Page 5
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1013 - Page 5
`
`
`
`

`
`
`
`Jdergo salt
`
`mp of Xan-
`s. Since the
`nhylline salt
`3—halotheo-
`as been at.-
`
`)f quinine,
`lcharacter—
`le than the
`_-report, the
`narcotics,
`e prepared
`
`ving the 8-
`.he unusual
`
`heophylline
`1g initiated
`uble 8-bro-
`
`Vitii readily
`esized and
`
`ted against
`3ro1notheo~
`ass.
`
`nphyllinates
`iiposed that,
`ore electro-
`mere acidic
`estable salts
`thine deriv-
`cur. On this
`acologically
`Iarrnaceuti-
`
`theophylli—
`5-nitrotheo—
`ice in mice
`-'llinate was
`ohylline. In
`3 5 g.
`n, has been
`_ced toxicity
`cleinulcent.
`rte rationale
`:k to the GI
`ns liberated
`
`‘genie quin-
`r times less
`.5 attributed
`:elygalactu-
`
`_ly useful as
`lll.
`
`fluenced by
`at a specific
`‘wed from-—
`
`1ysicochein—
`5 absorption,
`sential for a
`ration of ac-
`
`Tahle lII—Potentially Useful Salt Forms of Pharmaceutical Agents
`
`Salt-Forming Agent
`
`Compound Modified
`
`Nlcadificatitrn
`
`itc-ts-rem-e
`
`.-\cr».ty|aminoacetic acid
`.'\"—Acetyl—I.—asparagine
`N-Acel._vlcysti:1e
`atrlarnantoic acid
`.-tdipic acid
`ti‘-Alkylstrllamntes
`
`r\nt.hraquinone— l,5—disulI'onic acid
`Ara bogalactan sulfate larabino}
`Argininc
`
`Aspartale
`Betnine
`lrlisl133-carbu)xycl1romon~5—yloxy)alkanes
`Carnitinc
`at-{‘h|orn—m -toluenesulfonic acid
`Decanoate
`llincetyl sulfate
`Ilibenaylethylenediamine
`Dietliylamine
`lligiiaiat-yl phosphate
`lliortyl sulfosuccinate
`Fimhonic ipamoic) acid
`
`Fructose. 1,6-cliphosphoric acid
`
`tllucose 1 -phosphoric acid, glucose
`['l-[)l'!05|.')l1¢1]‘l(.‘ acid
`I.-tiltltamine
`l-lyrlrmcynaphthoate
`2-l-l-lmidaitolyllethylarnine
`lsoliutanolarnine
`Lauryl sulfate
`|.._\.rsine
`
`.-irlelhonesulfonic acid
`:'\'-i\«'lcl.hylglt1carninc
`
`.’\'-Vlet hylpiperazine
`."vir:rpholine
`‘_’-'\lirphtlialenesoltonic acid
`Uctan--etc
`Prolienecicl
`'i'.-mnir acid
`'|'heubroInine acetic acid
`It,4.5-'l‘riniethoxybenaoatc
`
`'l"romcthaminc
`
`Doxycycline
`Erythromycin
`Doxycycline
`Alkylbiguanides
`Piperazine
`Ampicillin
`Lincomycin
`Cephalexin
`Various alkaloids
`Cephalosporins
`orvSulfoben'Ly]penicillin
`Erythromycin
`Tetracycline
`T-(Aminoall<ylltheophyllines
`Metforrnin
`Propoxyphene
`l-leptaminol
`Thiamine
`Ampicillin
`Cephalosporins
`Tetracycline
`Vincamine
`Kanamycin
`2—Phenyl-3~niethylmorpholinc
`'l"et.racycline
`Erythromycin
`'l‘etrac_vcline
`Erythromycin
`Erythromyciri
`Bephenium
`Prostaglaiidin
`Tbeophylline
`Vincamine
`or-Sulfobenzylpenicillin
`Cephalosporins
`F‘ralidoxin1e(2- PAMt
`cr-Sulfobenzylpcnicillin
`Cephalosporinfi
`Phcnylbtit-azone
`Cephalosporins
`Propoxyphene
`l-leptaminol
`Pivampicillin
`Various amines
`Propmryphene
`Tetracycline
`Heptaminol
`Aspirin
`Dlnoprost. lprostaglanrlin l7‘;,,J
`
`Solubility
`t-hrltibility, activity, stability
`Combined effect useful in pneumonia
`Prolonged action
`Stability. toxicity, or:.{anoleptio propcrtie.-e
`Absorption {oral}
`Solubility
`F-baliility, absorption
`Prolonged act ion
`'l"osi:.-it_V
`.°~t.abilit.y, l1_vgrosropicit.y, Loxit-it_\'
`Solubility
`Gastric alJsorpt ion
`Act’.ivit_v_. prolonged prnph_vlan::t.ic effect
`Tr-xittity
`Organoleptic properth-_-s
`Prolonged at-tion
`.‘-Stability. hygroscopicity
`Prolonged action
`Reduced pain on injection
`Activity’
`Organoleptic properties
`Toxicity
`Toxicity
`.‘~1o|obilit_v
`5-iolubility
`l‘inlubilit_v
`l'n'nlubilii._v
`Solubility. activity. stability
`Toxicity
`Prolonged &(‘l.l<tI'|
`Stability
`Urganoleptic properties
`'l‘:otictty, stability. hygroscopic-ity
`
`htsslubi I it);
`"l‘oxiciI.y, stability, lIygrosc<.rpiril.).-'
`Reclucetl pain on injection
`'l‘oxicit.y, faster onset of action
`Reduced pain on in_ie<:tion
`Organnleptlc properties
`Prolonged action
`Urganolcptic propert it-s
`Prolongctl action
`Activity
`Urganolcptic properties
`Prolonged action
`Aim n'}'.lt.lI_1r't (oral!
`l‘l1ys'n-al state
`
`:31
`.31!
`as
`.-'1-I
`-3:71
`Fsfi
`.1‘.
`.3.‘-t
`.39. Fill
`fit
`H2
`GI?
`ii-I
`ti?»
`iitt
`ii?
`HR
`69
`Ti]. 71
`T.-‘
`Til
`T4
`T5
`TR
`T‘.
`
`:7
`
`5'.’
`To
`TE)
`htl
`h'1
`H15
`til
`‘'3
`Iii
`73
`Hit
`7‘-J
`H-1
`(:18
`R5
`tilt. is?
`83
`H9
`58
`Ettt
`9!
`
`tion, the relative toxicity, and the possible routes of ad-
`ministration (2).
`In a review in 1960, Miller and Holland (92) stated that.
`“rlifferent salts of the same drug rarely differ pharmaco-
`logically; the differences are usually based on the physical
`properties." In a subsequent review (93), Wagner ex-
`panded upon this statement, asserting that, although the
`nature of the biological responses elicited by a series of
`salts of the same parent compound may not differ appre-
`ciably, the intensities of response may differ markedly.
`The salt form is known to influence a number of physi-
`cochemical properties ofthe parent compound including
`dissolution rate, solubility, stability, and hygroscopicity.
`These properties, in turn, affect the availability and for-
`mulation characteristics of the drug. Consequently, the
`pharmaceutical industry has systematically engaged in
`extensive preformulation studies of the physicochemical
`properties of each new drug entity to determine the most
`suitable form for drug formulation. Published information
`concerning such studies, however, is sparse. Preforrnula-
`tion studies have been outlined, and the influence of the
`salt form on the volatility and hygroscopieity of an agent-
`under investigation was discussed (94).
`
`In one such study, methylpyridinium-2-aldoxime
`ipralidoxime} salts were investigated (95). This study set
`out to prepare a salt with water solubility adequate to allow
`intramuscular injection of a low volume (2-3 ml) thera-
`peutic dose. The original compound, the 111El;—l1lUCllCl9, had
`the disadvantages of limited aqueous solubility and ltigh
`potential toxicity, since its high iodide content. could result
`in iodisrn. On the basis of physiological compat.ibility,
`better water solubility, favorable stability. and relat.ively
`high percentage of oxirne, the chloride salt of pr-alirloxime
`was selected for therapeutic administration; it was claimed
`that “the anion usecl to form the salt can confer physical
`properties of importance and significance for the forum-
`lation and administration of the compound" {Q5}.
`Some physicochemical properties ofa series of mineral
`acid salts of lidocaine also were determined (96). While the
`hyd rochloride and hyclrobromiole were more hygroscopic.
`they were more soluble in a number of solvents than the
`nitrate, perchlorate, phosphate, or sulfate salts.
`Dissolution Rate——The dissolution rate of a pharma-
`ceutical agent is of major importance to the Formulator‘. In
`many cases, particularly with poorly soluble drtigs, this
`characteristic best reflects the bioavailability of the com-
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1013 - Page 6
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1013 - Page 6
`
`Vol. titi. Nrt l. :l'm1or::'_\-' I97? 3' 5
`
`
`
`

`
`
`
`administration of three different salts and the free acid,
`was the same as the rank order of their rates of dissolution
`in oitro. While the investigators ascribed these differences
`to the solubility properties of the salts, their experiments
`actually compared dissolution rates, not solubilities. The
`relative order of dissolution rates and mean mardi-rial blood
`levels was: potassium salt > calcium salt > free acid >
`benzathine salt.
`Nelson (100) determined dissolution rates for several
`weak acids and their sodium salts in media whose pl-{'3
`represented GI fluids. In all cases, the sodium salt. dis-
`solved more rapidly than the free acid. This finding re-
`solved the misconception that absorption of drugs is re-
`lated only to solubility in the appropriate medium; rather.
`solubility affects absorption only to the extent that it ef-
`fects dissolution rate. Absorption of drugs is a dynamit-
`process. and the ultimate solubility of a drug in fluid al
`absorption sites is of limited consequence since absorption
`prevents the attainment of saturated solutions. Therefore.
`dissolution rate, more than solubility, influences absorp-
`tion since it is a preceding process.
`In two subsequent studies, Nelson and coworkers fur-
`ther illustrated the effects of changing nonionized drugs
`into salts. A report concerning tolbut-amide {I01}, a weal
`acid, showed that the initial dissolution rate of tolbu tamide
`sodium was approximately 5000 times more rapid than the
`free acid in acidic media and 300 times more rapid in
`neutral media. This difference, measured in oitro. reflecterl
`the differences observed between the free acid and the salt
`when administered to htunan-subjects. Oral administration
`of tolbutamide sodium produced an immediate drop in
`blood sugar comparable to that produced by intravenous
`injection of the salt, while the slowly dissolving tolbuta
`inide produced a smooth, sustained fall in blood sugar
`(102).
`Correlation of urinary excretion rates and dissolution
`rates of tetracycline and some of its acid salts also was
`demonstrated by Nelson (103). The salts that exhibited
`greater in tiitro dissolution rates showed greater urinary
`excretion rates, indicating more rapid absorption.
`Benet {I04}, in a discussion of the biopharmaceutical
`basis for drug design, referred to the influence of the salt
`form on dissolution. He compared the dissolution rates ol
`tetracycline and tolbutarnide and their salts, as reporteil
`in the studies previously cited, and explained why the rates
`differ at the pl-l's exhibited by physiological fluids.
`Although salt formation usually increases the dissolution
`rat.e of a drug, studies with aluminum acetylsalicyla te l 105.
`106), warfarin sodium {107l. and benzphetamine panioalt
`(108) showed that. administration of the salt .~_.'i’oii'ed dis-
`solution of the drug and subsequent absorption compared
`to the nonionized form. This decrease appeared t.ii resuli
`from precipitation of an insoluble particle or film on the
`surface of the tablet. Such a phenomenon decreases the
`effective surface area and prevents deaggregation of the
`particles. Theoretical considerations of the processes
`controlling dissolution of an acid salt ofa base (108) and
`the sodium salt of a weak acid (109, 110) in reactive media
`have been discussed.
`
`Tablet processing and various formulation factors can
`decrease the dissolution rate of a salt. in human gastric juice
`over its nonioriized form (111). Granulation and tableting
`caused the dissolution rate of phenobarbital sodium tii
`
`decrease bu
`Therefore, 5
`the sodium:
`results were
`properties c
`]Lition may i
`Others he
`the dissolut
`form. Lin et
`
`and biologic.
`base of an e
`
`HCl, and pi‘
`the monoby
`base in 0.1 1
`water and p
`variation to
`experiment.
`monohydroi
`the implicai
`the activity
`must be con
`hydrocblori
`Some con
`formation o
`
`tionship lilel
`pearance of
`et oil. (114)
`of salts of a
`the Eu'ill.—ft'!l‘I2
`They state:
`dissolution
`be the case i.
`dissolving s
`more rapid
`forrnation o
`
`higicol ("oni
`Several re
`tion rate on
`
`(us, 117). C
`and salt. for"
`Solubilit;
`of a pharrns
`is usually a
`profile, the
`mulation of
`a primary fr
`uhility ofar
`and chemicr
`
`point. for a r
`lattice ener
`
`Solubility c
`perature. pi
`pH), and, tr:
`solute.
`
`Ari impor
`involves the
`ride salts of
`
`hility in gas‘
`ions. The er
`
`Salt forrn
`
`pound. As a rule. a pharmaceutical salt exhibits a higher
`dissoliition rate than l.he corresponding conjugate acid or
`base at no equal pl-I, even though they may have the same
`equilihriiiin soh.ilJilil._v. The explanation for this result lies
`in the processes that control dissolution.
`Dissolution can be described by a di ffusion layer model‘
`in terms of an equation developed by Nernst and Brunner
`1971:
`
`lEq. ii
`
`,
`..
`l)‘S
`dill’
`till = T H G — r I
`where W is the mass of the solute dissolved at time t,
`(ll/Wdt is the rate of mass transfer per unit time, D is the
`solute inoleculc diffusion coefficient, 5‘ is the surface area
`of the rlissoiving solid. ii. is t.he diffusion layer thiCli11€SS.
`t_' is the concent.ral'.ioi'i of the drug in t.he bulk solution at
`time if, and C,
`is the saturation solubility of the solute in
`the diffusion layer.
`The driving force for dissolul ion in Eq. 1 is the difference
`between the saturation solubility of the drug and the
`I.".t‘)l'1t'E‘]1ll'al'll)l'1 of the drug in the bulk fluid. If the drug is
`iioi rapidly absorbed after it dissolves, then C, the con-
`centration in the bulk solution. approaches C’, and the
`i..lissolin.ion rate is retarded. When this occurs. absorption
`is “absorption i'at.i3" limited (or "membrane transport"
`limited). if the absorption rate is rapid (or if the absorption
`rnai-is transfer coefficient is much larger than .DS/h. ofEq.
`it. however. ll‘ becornes negligible compared to C, and
`dissolui ion i'_:c.c.urs under "sink” conditions. Absorption is
`then S::IlCl to be dissolution rate |imit.ed, which is what oc-
`curs with most" poorly soluble drugs. In either case. an in-
`t-.reasc in
`as in salt. formation, increases dissolut.ion.
`!~i:-ilts olten speed dissolution by effectively acting as
`their own ln_ii’fers to alter the pH of the diffusion layer, thus
`increasing the solubility of the parent cofhpound, C,. in
`that la_\’€!r over its inherent solubility at the pH of the
`dis.»:olI_itioi'i medium. Hence, dissolution is controlled by
`solubility in the diffusion layer which, in turn, is deter-
`mined by the pH of that layer. The influence i'ifK_,.,, on the
`solubility term, (_‘,, and dissolutioii rate. should an accu-
`il'l1llli‘tl'.lt}l‘I of ions be allowed to oc.cur. will be treat-ed
`ater.
`Nclsoii {BS}. in a study of theophylline salts. was the first
`to show the coi‘relat.ion between diffusion l.ayei' pH and
`dissolution rate. The major impact. that. this study had on
`the pliarniaceiitii~al sciences was its conclusion that, if
`other factors remained constant._ the dissolutioii rate ofa
`compound determined the rate of buildup of blood levels
`vvitli time and the maxiinum levels obtained. Those salts
`of the acidic llieophylline with high diffiision layer pH's
`had grc.at.ei' in i_v'i.ro dissolution rates than those exhibiting
`a lower di1'i'usioii layer pl-l. And, indeed, the rank order of
`dissoliition rates correlated well with cliiiii:-ally determined
`blood levels. l-’resumal:il_v. the higher pH in the diffusion
`layer i'etai'ils l't_\'ClI‘(ll_\:"S‘«lS oftlie salt, thereby inaintaining
`the ‘c1Illt_Il‘tll‘ charge of the tlieiiphylliiiale ion. This report
`led to nisiiy additional studies which illustrate the influ-
`ence of the sail. form on dissolution and the beneficial ef-
`fects of cliai'i,v,'i1ip' [‘lUI]lDl1li.ECl drugs into salts.
`-luncher and Raaschou (99) dernoiisi'.rat.edthat. the rank
`order of peak blood levels of penicillin V. obtained upon
`
` '
`
`'l'.‘ii :iiil llnl" r'i_-i'iI-_'rii:v_i_- Iln: (-\ri.-a1t-ii:-i- l,‘l
`I-ii‘ Illll-'ll':'ill‘—'E ]|||!'|lII'.-'~|.'-1
`
`i-1 l'It’|' Iniiile-l-'_ ll1l,€.n-J11) Wu-.-'. l']'IlI1-'I‘ll .~:iiIi1:l_\'
`
`ll
`
`,4 Jiiirriiirl of l’.litir.ii1ur'i_'ti.ltf'nt' .‘i'r'ii'rii'i=.<
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1013 - Page 7
`Petitioner Mylan Pharmaceuticals Inc. — Exhibit 1013 — Page 7
`
`
`
`

`
`
`
`is free acid,
`Tdissolution
`2 differences
`
`.-xperirnents
`hilities. The
`iximal blood
`free acid >
`
`a for several
`whose pl-i's
`um salt dis-
`:-. finding re-
`drugs is re-
`liumzrather,
`nt that it of-
`s a dynamic
`g in tluid at
`e absorption
`s. Therefore.
`aces absorp—
`
`
`
`--,_—.-_.<_
`
`worl<ers fur-
`llll.7.(-‘fl drugs ‘
`llll l, a weak
`tolbutamide
`spid than l.he
`ore rapid in .
`trn_ rellected
`l and the salt
`lrninistration -
`liate drop in
`intravenous
`
`sing t.olbuta-
`l‘;luur.|
`.-iugar
`
`d rlissnlution
`alts also was
`rat exhiliited
`Eater urinary
`prion.
`Eirmaceutical
`ICE‘ oi" the salt
`uiion rates of
`I. as reported .
`wl1_\‘thr:1'aI'.es
`l fluids.
`he dissolution
`alicx-'lat.e 1.105,
`nine pamoate
`ll .-:lo1red dis-
`ion (J! srnpared
`ared to result
`If film on the
`iecreases the
`
`agation of the
`he processes
`ase {_lt’l:':l) and
`ear-l.ive media
`
`in factors can
`
`.11 gastric juice
`and tableting
`tal sodium to
`
`decrease but had the opposite effect on phenobarbital.
`Therefore, as a tablet dosage form, the dissolution rate of
`the sodium salt was slower t.han that of the free acid. These
`results were attributed to differences in the disintegrating
`properties of the tablets; in some instances, rapid disso-
`lution may in fact, be a problem for very soluble drugs.
`Others have illustrated a phenomenon that decreases
`the dissolution rate of a salt below that of its nonionized
`form. Lin et at. {J 12) studied the relationship between salts
`and biological activity by dissolving three salts and the free
`base of an experimental antihypertensive in water, 0.1 N
`HCl, and pH T2 phosphate buffer. The dissolution rate of
`the monohydrochloride salt was lower than that of the free
`base in 0.1 N HCl and higher than the free base in both
`water and phosphate buffer. These authors ascribed this
`variation t.o the common ion effect and substantiated it
`experimen tally. Although the biological activity of the
`monohyd rochloride was greater than that of the free base,
`the implications of altered absorption characteristics on
`the activity of any other hydrochloride salt in GI fluids
`must be considered. Similar results also were reported for
`hydrochloride salts of some tetracyclines (113).
`Some consideration must be given to the influence of salt
`formation on oral toxicity, which often reflects the rela-
`liunship bet.ween the in vino dissolution rate and the ap-
`pearance of drug in the circulation (114, 115}. Morozowich
`:21 at. (114) showed that the relative toxicities of a series
`of salts of a drug reflect the rate of absorption, providing
`the salt.-forming agents themselves are relatively nontoxic.
`They stated that “when absorption is rate-limited by
`dissolution of the salt in the gastrointestinal tract, as will
`be the case with slowly soluble salts, the toxicity of a slowly
`dissolving salt will most probably be lower than that of a
`more rapidly dissolving salt." The implications of salt
`lllI‘]'l'lal.lt}fl on toxicology will be discussed under Toxico-
`logical Corisiclerrrtiorts.
`Several reviews dealt with the influence of the dissolu-
`tion rate on drug availability and, in particular, salt effects
`l l 16.
`I 17}. Other reports illustrating the influence of salts
`and salt form on dissolution rate are listed in Table IV.
`Solubility—~Knowledge of the solubility characteristics
`of :2 pharmaceutical agent. is essential, because solubility
`is usually an important factor in the pharmacokinetic
`profile, the chemical stability, and, ultimately, the for-
`mulation of the drug. As discussed previously, it is certainly
`a primary l'actor\in controlling dissolution rates. The sol-
`ubility of a compound depends basically upon the physical
`and chemical properties of the solute; e.g., a lower melting
`point for a compound within a series reflects a decreased
`lattice energy, which would suggest a higher solubility.
`Solubility depends as well upon such elements as tem-
`perature, pressure, solvent properties [such as resulting
`pH l. and, to a lesser extent, the state of subdivision of the
`solute.
`An important solvent property which is often overlooked
`involves the common ion effect; in particular, hydrochlo-
`ride salts of drugs often exhibit less than desirable soluv
`hility in gastric juice because of the abundance of chloride
`ions. The equilibrium involved is shown in Scheme 1.
`
`ou+c1-._..,.,,, 7% tDH*l,... + tc1—i..,
`Scheme l'
`
`Salt. formation is perhaps one of the first approaches
`
`Table IV—Addil:ional References on Salt Form and
`Dissolution Rate
`
`Topic
`
`lilelereiice
`
`Dissolution rate of mixtures of weak acids and tribasic
`sodium phosphate
`Physiological availability and in uitro dissolution
`characteristics of some solid dosage formulations of
`aminosalicylic acid and its salts
`Biopharmceutics, rate of rlissolution: chronological
`bibliography
`Biopharmaceutics: rate ofdissolution in crtrn and in cioo
`Dissolution tests and interpretation ofanomalies observed
`in the dissolution process ot' sulfaquinoxaline based on
`salt formation
`ln|'|ur_-nce. of the dissolution rate of lithium tablets on side
`elllecis
`Dissolution kinetics of drugs in human gastric juice
`Comparison of dissolution and absorption rate:-'. of
`different cornrnercial aspirin tablets
`In uitro dissolution rates ofarninorex dosage forms and
`their correlation with in Lritro availability
`
`118
`llll
`
`L-.'.'‘S
`
`l
`
`»-0-A r-.'.-N.{O>—-
`
`..n..
`
`131
`[94
`135
`
`125
`
`considered as a means of increasing a cornpound’s water
`solubility. As with dissolution rates, however, salt forma-
`tion does not always confer greater solubility. Liberally
`dispersed throughout. the pharmaceutical literature are
`studies that compare the solubilities of different. salt forms
`of the same compound with those of its free acid or base
`(Table IV). Selection of the salt form exhibiting the desired
`solubility properties is critical, since these properties often
`dictate the formuiation characteristics of the drug.
`Phase solubility techniques were used to study the for-
`rnation of complex salts oftriamt.erene (127). The results
`indicated that the organic acid salts of basic drugs, such
`as amines, were more soluble in water than the corre-
`sponding inorganic (halide) saits. This consideration is
`important in the synthesis and selection of a salt form that.
`will exhibit enhanced bioavailability and desirable for-
`mulation characteristics.
`The hydrogen-ion concentration can significantly affect
`the solubility of a salt. Anderson (128) discussed the in-
`fluence of pH on the solubility of pharmaceuticals.
`Mathematical relationships between pH and solubility of
`therapeutically useful weak acids and bases and their salts
`were given along with some considerations in the formu-
`lation of solutions of these particular agents.
`An extensive study on the solubility interrelationships
`of the hydrochloride and free base of two pharmaceutically
`useful amines was reported (129). Mathematical equations
`describing the t.ot.al solubility at an arbitrary pH in terms
`of the independent. solubilities of the hydrochloride and
`free base species and the dissociation constant of the salt.
`were derived and fitted to eirperimental data with good
`results. This report elucidated the point that. while the
`solubility of the amine hydrochloride generally sets the
`maximum obtainable concentration for a given amine, the
`solubility of the free base and the pKa determine the
`maximum pH at which formulation as a solution is possible
`(assuming that. the desired concentration exceeds the free
`base solubility}. Shifting the pl-Lsolubility profile 1.o higher
`pH values for formulation purposes may require increasing
`the solubility of the free base. This increase might be ac-
`complished by using an appropriate cosolvent. Since the
`dissociation characteristics of carboxylic acids and other
`acidic organic species are similar to those of organic hy—
`drochlorides, it is expected that the pl-l—soluhiiity profiles
`
`
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1013 - Page 8
`Petitioner Mylan Pharmaceuticals Inc. — Exhibit 1013 — Page 8
`
`Vol. 56, No. .T,Jonnor_i- ff???"/‘ 7
`
`

`
`
`
`of these organic acids, although reversed, can be charac-
`terized theoretically using the same treatment.
`Several reports showed that the structure of-an organic
`salt-forming radical influences the solubility of t.he re-
`sulting salt. The water solubilities of 18 salts tcarboxylates.
`sulfates. sulfamates, and phosphates} of the weak base
`erythromyci n were dependent on the size. of the alley] group
`of the. acid (1301. In a study wi1;h N-alkylsulfamates of
`lincomycin (66), a similar phenomenon was observed:
`solubility of these salts decreased as the size of the alkyl
`group attached to the acidic function increased.
`Senior £131}, in a study on t.he formulation and prop-
`erties of the antibacterial chlorhesidine, determined the
`water soiubilities of 35 salts and the free base. He found
`that inorganic salts had remarkably low solubilities while
`those of the lower aliphatic acids proved to be somewhat
`more soluble. Hydroxylation of the acid increased solu-
`bility, since salt formation with polyhydroxy acids, par-
`ticularly the sugar acids, conferred extensive water solu-
`hiiity to the molecule.
`Several investigators reported the influence of the sol-
`ubility ofa drug on its formulation and subsequent avail-
`ability from the dosage form. In a discussion of the prep-
`aration and lorrntilation of epinephrine salts in an aerosol
`system using liquefied gas propellants, Sciarra cc of. (1232)
`pointed out that the. solubility characteristics ofthe agent
`are important. in two respects. First, the solubilit.y of the
`therapeutically active ingredient in the various propellalits
`is an important consideration if the product is to be used
`for either local action in the lungs or systemic therapy.
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket